Cleo Strengthens Cash Position with $1.7m R&D Tax Refund
Filed with ASX · · 2 pages · English
MELBOURNE, AUSTRALIA, 26th November 2025: Ovarian Cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO or the Company) is pleased to announce that it has received a cash refund of $1,716,580 from the Australian Government for its FY25 Research and Development (R&D) Tax Incentive claim. Following receipt of the refund, CLEO now holds a strong cash balance of ~$5.75 million as at 25t
Earlier from CLEO Diagnostics
- CLEO Appoints First Key Opinion Leader to Support US Market
- CLEO Significantly Expands Addressable Market
- CLEO Successfully Completes Stage 1 MDSAP Audit
- Cleo Receives Positive FDA Feedback
- Appendix 4E and 2025 Annual Report
Later from CLEO Diagnostics
- Trading Halt
- CLEO Raises $5m to Support U.S. Market Launch
- Quarterly activities and cashflow report
- CLEO Confirms Next-Gen Platform for Ovarian Cancer Test
- Appendix 4D and Half Yearly Accounts
Follow CLEO Diagnostics into a list and get an email when it puts out news.
Follow CLEO Diagnostics